Human serum albumin-encapsulated near-infrared hemicyanine photosensitizers for viscosity imaging and enhanced photodynamic therapy

The research successfully developed a novel dual-function near-infrared photosensitizer, CyI, which is encapsulated with human serum albumin (HSA) to form CyI-HSA nanocomplex that can simultaneously monitor the viscosity of cancer cell and enhance the efficacy of photodynamic therapy (PDT). In vitro experiments demonstrated that compared with CyI alone, CyI-HSA has superior water solubility and high photostability, and can effectively prevent aggregation-caused quenching (ACQ) caused by π-π stacking. Additionally, singlet oxygen quantum yield of CyI-HSA as high as 27.4 % under 658 nm laser irradiation, indicating significant PDT potential. Cellular experiments further revealed that CyI-HSA can monitor intracellular viscosity with high sensitivity, while generating a substantial amount of singlet oxygen, promoting PDT and cell apoptosis. Treatment of HepG-2 cells with 1 µmol/L CyI-HSA reduced cell viability by only 13 % (Laser = 100 mW cm⁻²). Therefore, as a kind of nano-photosensitizer integrating diagnostic and therapeutic functions, CyI-HSA has a broad prospect in the application of near-infrared hemicyanine photosensitizers in photodynamic therapy.